Index

Note: Page numbers of article titles are in **boldface** type.

A
Activated partial thromboplastin time, in coagulation testing in liver disease, 56–57
Acute liver failure
  coagulopathy of, 95–107
  clinical presentation of, 97–98
  bleeding during and after OLT, 98
  iatrogenic bleeding, 98
  spontaneous bleeding, 97
  described, 95
  frequency of, 95–96
  laboratory evaluation of, 98–100
  management of, 100–103
  pathophysiology of, 96–97
  described, 95
  severity of, 95–96
Anemia, in cirrhosis, 35
Anesthesia/anesthetics, in blood loss management in liver surgery, 148–150
Antifibrinolytic(s)
  in blood loss management in liver surgery, 150–151
  in ESLD management, 89–91

B
Bleeding
  during and after OLT, in coagulopathy of acute renal failure, 98
  hyperfibrinolysis and, 23
  iatrogenic, in coagulopathy of acute renal failure, 98
  in liver disease
    future directions in, 155–157
    risk assessment for, 155–156
  in liver surgery, 145–154
    described, 145–146
    management of, strategies to reduce blood loss in
      anesthesiologic, 148–150
      pharmacologic, 150–151
      surgical, 146–148
    risk factors associated with, 14–15
    spontaneous, in coagulopathy of acute renal failure, 97
Bleeding diathesis, in cirrhosis, 76–78
Bleeding time, platelet aggregation and, 14–15
Blood products
  in cirrhosis, 156
  in coagulopathy management in liver disease, 76–78

Budd–Chiari syndrome, 127–144
  causes of, 127
  classification of, 135–136
  clinical course of, 135–136
  described, 135
  EHPVO and, 139
  evaluation of, 129–130, 136–137
  noncirrhotic portal hypertension and, 139
  prevalence of, 135
  prognosis of, 137–138
  risk factors for, 127–129
  treatment of, 139

C

Child-Pugh score, 14

Chronic liver disease, PVT in, 134–135

Cirrhosis
  bleeding diathesis in, 76–78
  blood product and procoagulants in, 156
  coagulation cascade in, 1–9. See also Coagulation cascade, in cirrhosis.
  coagulopathy in patients with, 78–81
    management of
      dialysis catheter placement in, 80
      renal replacement therapy in, 80–81
      uremic platelet dysfunction, 79–80
    described, 55
  hypercoagulation in, consequences of, 111–113
  portal hypertension in, 76–78
  prognosis of, prothrombin time as index of, 58
  progression of, parenchymal extinction and, 156–157
  reduced platelet function in, relevance of, 15–16
  renal failure in patients with, 78–81
  superimposed coagulopathic conditions in, 33–42
    anemia, 35
      endogenous heparinoids, 34–35
      endothelial function, 36–37
      infection, 34–35
      platelet dysfunction, 35
      renal failure coagulopathy, 35–36
    thrombocytopenia in, relevance of, 15–16
    volume expansion in, 76–78

Coagulation
  heparin-like effect and, 44–47
  hepatic fibrogenesis and, 117–126. See also Hepatic fibrogenesis, coagulation and.
    in liver disease
      glycosaminoglycans effects on, 47–49
tests of, 55–61
  activated partial thromboplastin time, 56–57
  fibrinolysis, 58–59
  prothrombin time, 55–57
  thrombin generation test, 57–58
  thromboelastography, 59
  tissue factor–induced coagulation time, 55–57
in intravascular, accelerated, fibrinolysis and, 22–23
“waterfall” or “cascade” model of, described, 1
Coagulation cascade, in cirrhosis, 1–9
  amplification of procoagulants signal by thrombin generated on tissue
  factor–bearing cell, 3
  initiation of coagulation on tissue factor–bearing cells, 2–3
  plasma protease inhibitors in, 3–4
  propagation of thrombin generation on platelet surface, 3
  protein C/S thrombomodulin system in, 4–5
Coagulation disorders, in liver disease, future directions in, 155–157
Coagulation system, liver disease and, 5–7, 110–113
Coagulopathy(ies)
in liver disease, 73–85
  cirrhosis, 78–81. See also Cirrhosis, coagulopathy in patients with.
  management of, 73–85
    blood products in, 76–78
    packed red blood cells in, 75
    plasma transfusion in, 73–74
      TRALI due to, 74–75
    platelets in, 75
    volume contraction therapy in, 81
    volume expanders in, 76–78
  of acute liver failure, 95–107. See also Acute liver failure, coagulopathy of.
renal failure, in cirrhosis, 35–36

D
Dialysis catheter placement, in coagulopathy management in cirrhosis patients, 80
Diathesis, bleeding, in cirrhosis, 76–78
Direct stellate cell activation, in hepatic fibrogenesis, 119–122

E
EHPVO. See Extrahepatic portal vein obstruction (EHPVO).
Endogenous heparinoids, cirrhosis and, 34–35
Endothelial function, cirrhosis and, 36–37
End-stage liver disease (ESLD), management of, 87–93
  antifibrinolytic drugs in, 89–91
  pro-coagulants in, therapeutic vs. prophylactic therapy in, 91
  rFVIIa in, 87–89
ESLD. See End-stage liver disease (ESLD).
Extrahepatic portal vein obstruction (EHPVO)
  Budd–Chiari syndrome and, 139
    in childhood, 131–132
    nonmalignant, noncirrhotic, in adults, 132–134
Fibrinolysis
accelerated intravascular coagulation and, 22–23
in coagulation testing in liver disease, 58–59
Fibrinolytic system, imbalance of, 21–22
Fibrogenesis, hepatic, coagulation and, 117–126. See also Hepatic fibrogenesis, coagulation and.
Fibrosis(es), hepatic, following chronic liver injury, described, 117–118

Glycosaminoglycans
coagulation effects of, 47–49
in liver disease and liver transplantation, 47–49
therapeutic implications of, 49

Hemostasis, primary, standard diagnostic tests of, 12
Hemostatic agents, topical, in blood loss management in liver surgery, 150
Hemostatic system, liver failure effects on, 33
Heparin-like effects, in liver disease and liver transplantation, 43–53. See also Liver disease, heparin-like effect in.
Heparinoid(s), endogenous, cirrhosis and, 34–35
Hepatic fibrogenesis
clotting in, 118–119
cogulation and, 117–126
clinical evidence of, 118–119
direct stellate cell activation in, 119–122
epidemiology of, 118–119
microthrombi and hepatic damage in animal models, 118
pathogenic mechanisms of, 119–122
potential therapeutic implications, 122–123
microthrombi and hepatic damage in animal models, 118
Hepatic fibrosis, following chronic liver injury, described, 117–118
Hypercoagulation
defined, 109
in cirrhosis
consequences of, 111–113
described, 110–111
in liver disease, 109–116
Hyperfibrinolysis
in liver disease, 21–31
bleeding and, 23
diagnostic tests in, 25
pathophysiology of, 21–23
treatment of, 24, 26
in liver transplantation, 24
Hypertension, portal
in cirrhosis, 76–78
noncirrhotic, Budd–Chiari syndrome and, 139
I

Iatrogenic bleeding, in coagulopathy of acute renal failure, 98

Infection(s)
  - cirrhosis and, 34–35
  - heparin-like effect and, 44–47

INR. See *International normalized ratio (INR)*.

International normalized ratio (INR), of prothrombin time, in MELD score, unreliable measures, perspective on, 70

International normalized ratio (INR)
  - in liver disease
    - described, 69
    - implementation of, 156
    - limitations of, 68
    - of prothrombin time, in MELD score
      - reliable measure, 63–66
        - generic causes of variation, 64
        - liver-specific causes of variation, 64
      - unreliable measure, 67–71
        - described, 69–70
  - “International normalized ratio (INR) problem,” 69–70

Intravascular coagulation, accelerated, fibrinolysis and, 22–23

L

Liver disease
  - bleeding in
    - future directions in, 155–157
    - risk assessment for, 155–156
  - chronic, PVT in, 134–135
  - coagulation in
    - disorders in, future directions in, 155–157
    - glycosaminoglycans effects on, 47–49
    - tests of, 55–61. See also *Coagulation, in liver disease, tests of.*
    - coagulation system and, 5–7, 110–113
    - coagulopathy in, 73–85. See also *Coagulopathy(ies), in liver disease.*
    - glycosaminoglycans effects on, 47–49
    - heparin-like effect in, 43–53
      - coagulation, 44–47
      - described, 44–47
      - infection and, 44–47
    - hypercoagulation in, 109–116. See also *Hypercoagulation.*
    - hyperfibrinolysis in, 21–31. See also *Hyperfibrinolysis, in liver disease.*
    - INR in
      - described, 69
      - implementation of, 156
    - platelet and platelet function testing in, 11–20. See also *Platelet(s), in liver disease.*

Liver failure
  - acute, coagulopathy of, 95–107. See also *Acute liver failure, coagulopathy of.*
  - hemostatic system effects of, 33

Liver surgery, bleeding in, 145–154. See also *Bleeding, in liver surgery.*
Liver transplantation
- glycosaminoglycans effects on, 47–49
- heparin-like effect in, 43–53
  - described, 46–47
- hyperfibrinolysis in, 24
  - orthotropic, bleeding during and after, in coagulopathy of acute renal failure, 98

M
Macrovascular thrombotic disease, hypercoagulation in cirrhosis and, 111–112
MELD score. See Model for End-stage Liver Disease (MELD) score.
- Microthrombus(i), intrahepatic, tissue ischemia and fibrosis due to, 119
- Microvascular thrombotic disease, hypercoagulation in cirrhosis and, 112–113
- Model for End-stage Liver Disease (MELD), determinants of, 68
- Model for End-stage Liver Disease (MELD) score
  - as predictor of survival, 64–65
  - INR of prothrombin time in
    - limitations of, 68
    - reliable measure, 63–66
    - variation in
      - generic causes, 64
      - liver-specific causes, 64
    - unreliable measure, 67–71
      - described, 69–70
      - perspective on, 70

N
Noncirrhotic portal hypertension, Budd–Chiari syndrome and, 139
- Nonmalignant, noncirrhotic extrahepatic portal vein obstruction (EHPVO), in adults, 132–134

O
- OLT. See Orthotropic liver transplantation (OLT).
- Orthotropic liver transplantation (OLT), bleeding during and after, in coagulopathy of acute renal failure, 98

P
- Packed red blood cells, in coagulopathy management in liver disease, 75
- Parenchymal extinction, 117–126
  - cirrhosis progression due to, 156–157
  - intrahepatic microthrombi causing tissue ischemia and fibrosis with, 119
- PFA-100. See Platelet function analyser-100 (PFA-100).
- Plasma protease inhibitors, in coagulation cascade in cirrhosis, 3–4
- Plasma transfusion, in coagulopathy management in liver disease, 73–74
- Platelet(s)
  - abnormalities of, in liver disease, 11
  - described, 11
  - in coagulopathy management in liver disease, 75
in liver disease, **11–20**
- abnormalities of, 11
- described, 13–14
  - surface of, thrombin generation on, propagation of, 3
Platelet activation, under conditions of flow, 12–13
Platelet adhesion, under conditions of flow, 12–13
Platelet aggregation, bleeding time and, 14–15
Platelet dysfunction, in cirrhosis, 35
Platelet function, reduced, in cirrhosis, relevance of, 15–16
Platelet function analyser-100 (PFA-100), 15
Platelet function testing, in liver disease, **11–20**

Portal hypertension
- in cirrhosis, 76–78
  - noncirrhotic, Budd–Chiari syndrome and, 139

Portal vein thrombosis (PVT), **127–144**
- causes of, 127
- described, 130–131
- EHPVO in childhood, 131–132
- evaluation of, 129–130
- in chronic liver disease, 134–135
- risk factors for, 127–129

Pro-coagulant(s), in ESLD management, therapeutic vs. prophylactic therapy, 91
Procoagulants(s)
- in blood loss management in liver surgery, 151
- in cirrhosis, 156

Protein C/S thrombomodulin system, in coagulation cascade in cirrhosis, 4–5

Prothrombin time
- as index of prognosis in cirrhosis, 58
- in coagulation testing in liver disease, 55–57
- INR of, in MELD score
  - reliable measure, **63–66**. See also *Model for End-stage Liver Disease (MELD) score, INR of prothrombin time in, reliable measure.*
  - unreliable measure, **67–71**. See also *Model for End-stage Liver Disease (MELD) score, INR of prothrombin time in, unreliable measure.*

PVT. See *Portal vein thrombosis (PVT).*

**R**

Recombinant activated factor VIIa (rFVIIa), in ESLD management, 87–89
Red blood cells, packed, in coagulopathy management in liver disease, 75
Renal failure, in cirrhosis patients, 78–81
Renal failure coagulopathy, in cirrhosis, 35–36
Renal replacement therapy, in coagulopathy management in cirrhosis patients, 80–81
rFVIIa. See *Recombinant activated factor VIIa (rFVIIa).*

**S**

Superimposed coagulopathic conditions, in cirrhosis, **33–42**. See also specific conditions and *Cirrhosis, superimposed coagulopathic conditions in.*
T
Thrombin
  generated on tissue factor–bearing cell, amplification of procoagulants signal by, 3
  generation on platelet surface, propagation of, 3
Thrombin generation test, in coagulation testing in liver disease, 57–58
Thrombocytopenia, in cirrhosis, relevance of, 15–16
Thromboelastography, in coagulation testing in liver disease, 59
Thrombophilia. See also Hypercoagulation.
  defined, 109
  evaluation of, 129–130
Thrombosis(es)
  portal vein, 127–144. See also Portal vein thrombosis (PVT).
  protection from, protein C/S thrombomodulin system in, 4–5
Tissue factor–bearing cells
  amplification of procoagulants signal by thrombin generated on, 3
  coagulation on, initiation of, 2–3
Tissue factor–induced coagulation time, in coagulation testing in liver disease, 55–57
TRALI. See Transfusion-related lung injury (TRALI).
Transfusion(s), plasma, in coagulopathy management in liver disease, 73–74
Transfusion-related lung injury (TRALI), 74–75
Transplantation, liver. See Liver transplantation.

U
Uremic platelet dysfunction, in cirrhosis patients, 79–80

V
Volume contraction therapy, in coagulopathy management in liver disease, 81
Volume expansion, in cirrhosis, 76–78